SHIN NIPPON BIOMEDICAL, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 10%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Feb 6, 2026 11:30 am JST Earnings

2395 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 【J-GAAP】

Earnings Report

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. <2395> [TSE Prime] announced its financial results at noon (11:30) on February 6th. The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) decreased 24.6% from the same period last year to 3.11 billion yen.

In addition, the full-year forecast for consolidated ordinary profit has decreased 9.7%, from the previous forecast of 5.92 billion yen to 5.35 billion yen (compared to 6.45 billion yen in the previous period), leading to an increase in the profit decline rate from 8.1% to 17.0%. However, the full-year forecast for consolidated net income has been revised upward 0.3%, from the previous forecast of 3.55 billion yen to 3.56 billion yen (compared to 4.92 billion yen in the previous period), and the declining rate is expected to decrease from 27.9% to 27.7%.

Based on the full-year plan announced by the company after the downward revision, our estimate of the consolidated ordinary profit for the October to March period (second half) has decreased 13.3%, from the previous forecast of 4.30 billion yen to 3.72 billion yen (compared to 4.62 billion yen in the same period of the previous year), leading to an increase in the profit decline rate from 6.9% to 19.4%.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit dropped to 1.49 billion yen, a 35.4% decrease compared to the same period last year. The operating profit margin decreased from 18.6% in the same period last year to 15.2%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2023	17,984	2,535	4,884	3,794	91.1	69.6	Feb 2, 2024	J-GAAP
Apr - Dec, 2024	22,235	1,893	4,138	3,205	77.0	64.2	Feb 5, 2025	J-GAAP
Apr - Dec, 2025	21,195	1,027	3,119	2,270	54.5	58.3	Feb 6, 2026	J-GAAP
YoY	-4.7%	-45.7%	-24.6%	-29.2%	-29.2%

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2025 Prev	18,506	3,501	4,300	2,489	59.8	30	Nov 7, 2025	J-GAAP
Oct - Mar, 2025 New	15,932	2,551	3,726	2,500	60.1	30	Feb 6, 2026	J-GAAP
Revision Rate	-13.9%	-27.1%	-13.3%	+0.4%	+0.4%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2026 Prev	33,272	3,550	5,927	3,550	85.3	50	May 8, 2025	J-GAAP
Mar, 2026 New	30,698	2,600	5,353	3,561	85.5	50	Feb 6, 2026	J-GAAP
Revision Rate	-7.7%	-26.8%	-9.7%	+0.3%	+0.3%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024	19,905	2,905	4,621	3,593	86.3	30	May 8, 2025	J-GAAP
Oct - Mar, 2025 Guidance	15,932	2,551	3,726	2,500	60.1	30	Feb 6, 2026	J-GAAP
YoY	-20.0%	-12.2%	-19.4%	-30.4%	-30.4%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	26,450	4,162	7,015	5,531	132.9	50	May 8, 2024	J-GAAP
Mar, 2025	32,413	2,985	6,450	4,924	118.3	50	May 8, 2025	J-GAAP
Mar, 2026 Guidance	30,698	2,600	5,353	3,561	85.5	50	Feb 6, 2026	J-GAAP
YoY	-5.3%	-12.9%	-17.0%	-27.7%	-27.7%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2024	9,727	1,813	2,309	1,874	45.0	18.6	Feb 5, 2025	J-GAAP
Jan - Mar, 2025	10,178	1,092	2,312	1,719	41.3	10.7	May 8, 2025	J-GAAP
Apr - Jun, 2025	6,477	-340	515	260	6.3	-5.2	Aug 5, 2025	J-GAAP
Jul - Sep, 2025	8,289	389	1,112	801	19.2	4.7	Nov 7, 2025	J-GAAP
Oct - Dec, 2025	6,429	978	1,492	1,209	29.1	15.2	Feb 6, 2026	J-GAAP
YoY	-33.9%	-46.1%	-35.4%	-35.5%	-35.5%